DK1214416T3 - Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler - Google Patents

Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler

Info

Publication number
DK1214416T3
DK1214416T3 DK00960857T DK00960857T DK1214416T3 DK 1214416 T3 DK1214416 T3 DK 1214416T3 DK 00960857 T DK00960857 T DK 00960857T DK 00960857 T DK00960857 T DK 00960857T DK 1214416 T3 DK1214416 T3 DK 1214416T3
Authority
DK
Denmark
Prior art keywords
antigen
replication
immune response
adenoviral vector
stimulate
Prior art date
Application number
DK00960857T
Other languages
Danish (da)
English (en)
Inventor
Joerg Schneider
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1214416(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of DK1214416T3 publication Critical patent/DK1214416T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00960857T 1999-09-21 2000-09-20 Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler DK1214416T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
PCT/GB2000/003601 WO2001021201A2 (fr) 1999-09-21 2000-09-20 Utilisation d'un vecteur adenoviral pauvre en replications pour stimuler la reponse immunitaire des lymphocytes t cd8+ contre l'antigene

Publications (1)

Publication Number Publication Date
DK1214416T3 true DK1214416T3 (da) 2005-08-29

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00960857T DK1214416T3 (da) 1999-09-21 2000-09-20 Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler

Country Status (12)

Country Link
EP (2) EP1612269A1 (fr)
JP (1) JP2003509470A (fr)
CN (1) CN1391609A (fr)
AT (1) ATE295421T1 (fr)
AU (1) AU762894B2 (fr)
BR (1) BR0014138A (fr)
CA (1) CA2384806A1 (fr)
DE (1) DE60020136T2 (fr)
DK (1) DK1214416T3 (fr)
ES (1) ES2241653T3 (fr)
GB (1) GB9922361D0 (fr)
WO (1) WO2001021201A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP4654026B2 (ja) * 2002-05-20 2011-03-16 独立行政法人科学技術振興機構 Ｂｃｇワクチンとその利用
WO2004037294A2 (fr) 2002-10-23 2004-05-06 Crucell Holland B.V. Nouveaux parametres pour vaccins a base d'adenoviraux recombinants
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
WO2008063555A2 (fr) * 2006-11-17 2008-05-29 Genetronics, Inc. Méthodes accroissant la réponse immunitaire par vaccination assistée par électroporation, et renfort
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
US20090092638A1 (en) * 2007-09-14 2009-04-09 Institut Pasteur And Inserm Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
WO2014063832A1 (fr) * 2012-10-28 2014-05-01 Bavarian Nordig A/S Promoteur pr13.5 pour lymphocytes t robustes et réponses d'anticorps
CN110678197A (zh) 2017-03-15 2020-01-10 牛津生物医学（英国）有限公司 方法
JP2023500436A (ja) * 2019-10-16 2023-01-06 キャンサー・リサーチ・テクノロジー・リミテッド がん処置のためのベクター
US20230310591A1 (en) 2021-12-07 2023-10-05 Vaccitech (Uk) Limited Vaccine Boost Methods and Compositions
WO2024218165A1 (fr) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Vaccin à vecteurs viraux contre le vph

Also Published As

Publication number Publication date
BR0014138A (pt) 2002-05-21
AU7302400A (en) 2001-04-24
GB9922361D0 (en) 1999-11-24
CA2384806A1 (fr) 2001-03-29
JP2003509470A (ja) 2003-03-11
CN1391609A (zh) 2003-01-15
EP1612269A1 (fr) 2006-01-04
AU762894B2 (en) 2003-07-10
WO2001021201A3 (fr) 2001-10-18
WO2001021201A2 (fr) 2001-03-29
EP1214416A2 (fr) 2002-06-19
EP1214416B1 (fr) 2005-05-11
ATE295421T1 (de) 2005-05-15
DE60020136D1 (de) 2005-06-16
DE60020136T2 (de) 2006-02-23
ES2241653T3 (es) 2005-11-01

Similar Documents

Publication Publication Date Title
DK1214416T3 (da) Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler
Babiuk et al. Adenoviruses as vectors for delivering vaccines to mucosal surfaces
DK0724642T4 (da) Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis
WO2001075087A3 (fr) Variantes de lasubtilisine
DE69229476D1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
ATE347599T1 (de) Tuberkulose impfstoff
WO1998008542A3 (fr) Composes et procedes destines au traitement et au diagnostic d'infections mycobacteriennes
ATE212058T1 (de) Herstellung von einer immunantwort gegen prostat- spezifisches antigen (psa)
EE200300100A (et) Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon
JP2003509470A5 (fr)
DE69230671D1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
WO2003011331A3 (fr) Matieres et techniques relatives a des strategies de vaccination ameliorees
WO2001040313A3 (fr) Proteines immunoregulatrices felines, molecules d'acide nucleique et leurs utilisations
WO2000063406A3 (fr) Vecteurs adenoviraux possedant des acides nucleiques codant pour des molecules immunomodulatrices
WO2005011571A3 (fr) Proteines du noyau du virus de l'hepatite utilisees comme plateformes de vaccins et leur utilisation
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
DK1272652T3 (da) Herpesvirus til immunmodulation
WO1999047558A3 (fr) Nouvelles formes de protèines de co-stimulation des lymphocytes t, molècules d'acide nuclèique et leur utilisation
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
EP0763205A4 (fr) Sequences d'acides nucleiques regulant l'expression de genes specifiques aux poumons
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
WO2002016591A3 (fr) 49937, 49931, et 49933, nouveaux elements de la famille des transporteurs humains et utilisation de ces derniers
WO2003075849A3 (fr) Composition et procede pour ameliorer la reponse immunitaire